(LOSS) EARNINGS PER SHARE |
(LOSS) EARNINGS PER SHARE Basic earnings (loss) per share is computed by dividing net income (loss) attributable to American Renal Associates Holdings, Inc., net of the change in the difference between the estimated fair values of contractual noncontrolling interest put provisions and estimated fair values for accounting purposes of the related noncontrolling interests, by the weighted-average number of common shares outstanding during the applicable period, less unvested restricted stock. Diluted earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the applicable period, plus the dilutive effect of outstanding options, using the treasury stock method and the average market price of the Company’s common stock during the applicable period. Certain shares related to some of the Company’s outstanding stock options were excluded from the computation of diluted earnings per share because they were anti-dilutive in the periods presented, but could be dilutive in the future. | | | | | | | | | | | | | | 2017 | | 2016 | | Basic | |
| | |
| | Net (loss) income attributable to American Renal Associates Holdings, Inc. | $ | (1,251 | ) | | $ | 3,756 |
| | Change in the difference between the estimated fair values of contractual noncontrolling interest put provisions and estimated fair values for accounting purposes of the related noncontrolling interests | (11,083 | ) | | — |
| | Net (loss) income attributable to American Renal Associates Holdings, Inc. for basic earnings per share calculation | $ | (12,334 | ) | | $ | 3,756 |
| | Weighted-average common shares outstanding used to calculate basic net income (loss) per share | 30,907,482 |
| | 22,213,967 |
| | (Loss) earnings per share, basic | $ | (0.40 | ) | | $ | 0.17 |
| | Diluted | |
| | |
| | Net (loss) income attributable to American Renal Associates Holdings, Inc. | $ | (1,251 | ) | | $ | 3,756 |
| | Change in the difference between the estimated fair values of contractual noncontrolling interest put provisions and estimated fair values for accounting purposes of the related noncontrolling interests | (11,083 | ) | | — |
| | Net (loss) income attributable to American Renal Associates Holdings, Inc. for diluted earnings per share calculation | $ | (12,334 | ) | | $ | 3,756 |
| | Weighted-average common shares outstanding, basic | 30,907,482 |
| | 22,213,967 |
| | Weighted-average effect of dilutive securities: | |
| | |
| | Effect of assumed exercise of stock options | — |
| | 571,703 |
| | Weighted-average common shares outstanding used to calculate diluted net income (loss) per share | 30,907,482 |
| | 22,785,670 |
| | (Loss) earnings per share, diluted | $ | (0.40 | ) | | $ | 0.16 |
| | Outstanding options excluded as impact would be anti-dilutive | 1,315,091 |
| | 116,937 |
| |
|